SRPT Share Price

Open 32.55 Change Price %
High 32.63 1 Day -1.25 -3.83
Low 31.22 1 Week -4.72 -13.06
Close 31.41 1 Month 1.51 5.05
Volume 1611097 1 Year 19.30 159.37
52 Week High 63.73
52 Week Low 8.00
SRPT Important Levels
Resistance 2 32.72
Resistance 1 32.18
Pivot 31.75
Support 1 30.64
Support 2 30.10
NASDAQ USA Most Active Stocks
ASTI 0.01 0.00%
QCOM 54.88 -12.72%
QCOM 54.88 -12.72%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
More..
NASDAQ USA Top Gainers Stocks
EDMC 0.02 100.00%
CPSL 0.10 66.67%
LOCM 0.09 50.00%
ACFN 0.30 30.43%
LTRE 2.85 29.55%
WRES 0.09 28.57%
QKLS 0.14 27.27%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
QTWW 0.08 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Sarepta Therapeutics, Inc. (NASDAQ: SRPT)

SRPT Technical Analysis 1.5
As on 23rd Jan 2017 SRPT Share Price closed @ 31.41 and we RECOMMEND Buy for LONG-TERM with Stoploss of 28.14 & Sell for SHORT-TERM with Stoploss of 34.15 we also expect STOCK to react on Following IMPORTANT LEVELS.
SRPT Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
SRPT Other Details
Segment EQ
Market Capital 539801792.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.sareptatherapeutics.com
SRPT Address
SRPT
215 First Street
Suite 415
Cambridge, MA 02142
United States
Phone: 857-242-3700
Interactive Technical Analysis Chart Sarepta Therapeutics, Inc. ( SRPT NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Sarepta Therapeutics, Inc.
SRPT Business Profile
Sarepta Therapeutics Inc., formerly AVI BioPharma, Inc., biopharmaceutical company focused on the discovery and development of ribonucleic acid (RNA)-based therapeutics for the treatment of rare and infectious diseases. Its product candidates include Eteplirsen, AVI-6002, AVI-6003, and AVI-7100. As of December 31, 2011, the Company primarily focused on advancing the development of its Duchenne muscular dystrophy drug candidates, including its lead product candidate, eteplirsen, which is in a Phase IIb trial. It is also focused on developing therapeutics for the treatment of infectious diseases, including its lead infectious disease programs aimed at the development of drug candidates for the Ebola and Marburg hemorrhagic fever viruses. program focuses on the development of disease-modifying therapeutic candidates for Duchenne muscular dystrophy (DMD). It initiated a Phase IIb trial for eteplirsen in August 2011 with an objective of initiating a pivotal trial subsequent to 2011.